|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM347050662 |
| 003 |
DE-627 |
| 005 |
20231226032913.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109130
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1156.xml
|
| 035 |
|
|
|a (DE-627)NLM347050662
|
| 035 |
|
|
|a (NLM)36189576
|
| 035 |
|
|
|a (PII)S1521-6616(22)00211-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mountz, John D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.10.2022
|
| 500 |
|
|
|a Date Revised 02.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Published by Elsevier Inc.
|
| 520 |
|
|
|a Here, we report a case of atopic dermatitis (AD) in a patient who received biweekly doses of dupilumab, an antibody against the IL-4 receptor α chain (IL-4Rα). Single cell RNA-sequencing showed that naïve B cells expressed the highest levels of IL4R compared to other B cell subpopulations. Compared to controls, the dupilumab-treated patient exhibited diminished percentages of IL4R+IGHD+ naïve B cells and down-regulation of IL4R, FCER2 (CD23), and IGHD. Dupilumab treatment resulted in upregulation of genes associated with apoptosis and inhibition of B cell receptor signaling and down-regulation of class-switch and memory B cell development genes. The dupilumab-treated patient exhibited a rapid decline in COVID-19 anti-spike and anti-receptor binding domain antibodies between 4 and 8 and 11 months post COVID-19 vaccination. Our data suggest that intact and persistent IL-4 signaling is necessary for maintaining robust survival and development of naïve B cells, and maintaining a long term vaccine response
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a COVID-19 vaccination
|
| 650 |
|
4 |
|a Dupilumab
|
| 650 |
|
4 |
|a IL-4 receptor
|
| 650 |
|
4 |
|a Memory B cells
|
| 650 |
|
4 |
|a Naive B cells
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, B-Cell
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 650 |
|
7 |
|a dupilumab
|2 NLM
|
| 650 |
|
7 |
|a 420K487FSG
|2 NLM
|
| 650 |
|
7 |
|a RNA
|2 NLM
|
| 650 |
|
7 |
|a 63231-63-0
|2 NLM
|
| 700 |
1 |
|
|a Gao, Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ponder, David M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Shanrun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Chiao-Wang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Alduraibi, Fatima
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sullivan, Kathryn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pat, Betty
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dell'Italia, Louis J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hsu, Hui-Chen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 244(2022) vom: 21. Nov., Seite 109130
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:244
|g year:2022
|g day:21
|g month:11
|g pages:109130
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109130
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 244
|j 2022
|b 21
|c 11
|h 109130
|